NASDAQ:MEIP - MEI Pharma Stock Price, Forecast & News

MEI Pharma trades on the NASDAQ under the ticker symbol "MEIP."

MEI Pharma Inc (NASDAQ:MEIP) issued its earnings results on Thursday, February, 6th. The company reported ($0.26) earnings per share for the quarter, missing analysts' consensus estimates of ($0.15) by $0.11. The company earned $1.01 million during the quarter, compared to analyst estimates of $1.24 million. MEI Pharma had a negative net margin of 825.55% and a negative return on equity of 70.99%. View MEI Pharma's Earnings History.

MEI Pharma is scheduled to release their next quarterly earnings announcement on Thursday, May 14th 2020. View Earnings Estimates for MEI Pharma.

2 brokerages have issued 1 year target prices for MEI Pharma's shares. Their forecasts range from $10.00 to $10.00. On average, they expect MEI Pharma's stock price to reach $10.00 in the next year. This suggests a possible upside of 418.1% from the stock's current price. View Analyst Price Targets for MEI Pharma.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MEI Pharma in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for MEI Pharma.

News headlines about MEIP stock have been trending somewhat positive recently, according to InfoTrie. The research group identifies positive and negative news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. MEI Pharma earned a media sentiment score of 1.1 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for MEI Pharma.

Some companies that are related to MEI Pharma include Radius Health (RDUS), Applied Therapeutics (APLT), Phathom Pharmaceuticals (PHAT), Myovant Sciences (MYOV), Cytokinetics (CYTK), Amphastar Pharmaceuticals (AMPH), Dova Pharmaceuticals (DOVA), Rhythm Pharmaceuticals (RYTM), Collegium Pharmaceutical (COLL), CannTrust (CNTTF), Phoenix Tree (IMAB), Stoke Therapeutics (STOK), DiaMedica Therapeutics (DMCAF), Aprea Therapeutics (APRE) and Frequency Therapeutics (FREQ).

Based on aggregate information from My MarketBeat watchlists, some companies that other MEI Pharma investors own include Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Novavax (NVAX), Rigel Pharmaceuticals (RIGL), Verastem (VSTM), Catalyst Pharmaceuticals (CPRX), Ocular Therapeutix (OCUL), Onconova Therapeutics (ONTX), Opko Health (OPK) and Actinium Pharmaceuticals (ATNM).

MEI Pharma's stock is owned by a variety of of retail and institutional investors. Top institutional investors include NEA Management Company LLC (8.38%), BVF Inc. IL (5.04%), Renaissance Technologies LLC (2.82%), State Street Corp (1.17%), Point72 Asset Management L.P. (0.80%) and Geode Capital Management LLC (0.74%). Company insiders that own MEI Pharma stock include Brian G Drazba, Christine Anna White, Daniel P Phd Gold, David M Urso and Thomas C Reynolds. View Institutional Ownership Trends for MEI Pharma.

MEIP stock was sold by a variety of institutional investors in the last quarter, including Jacobs Levy Equity Management Inc., Oxford Asset Management LLP, New York State Common Retirement Fund and Connor Clark & Lunn Investment Management Ltd.. View Insider Buying and Selling for MEI Pharma.

MEIP stock was purchased by a variety of institutional investors in the last quarter, including BVF Inc. IL, NEA Management Company LLC, Point72 Asset Management L.P., Geode Capital Management LLC, Renaissance Technologies LLC, Panagora Asset Management Inc., State Street Corp and DAVENPORT & Co LLC. Company insiders that have bought MEI Pharma stock in the last two years include Brian G Drazba, Christine Anna White, Daniel P Phd Gold and Thomas C Reynolds. View Insider Buying and Selling for MEI Pharma.

Shares of MEIP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of MEIP stock can currently be purchased for approximately $1.93.

MEI Pharma has a market capitalization of $204.58 million and generates $4.91 million in revenue each year. The company earns $-16,820,000.00 in net income (profit) each year or ($0.62) on an earnings per share basis. MEI Pharma employs 32 workers across the globe.View Additional Information About MEI Pharma.

The official website for MEI Pharma is http://www.meipharma.com/.

MEI Pharma's mailing address is 3611 VALLEY CENTER DRIVE, SAN DIEGO CA, 92130. The company can be reached via phone at 858-369-7100 or via email at [email protected]